Skip to content
Esophageal Cancer Action Network Logo
  • ABOUT US
    • OUR STORY
    • FINANCIAL REPORTING
    • BOARD OF DIRECTORS
  • FACTS
    • ABOUT ESOPHAGEAL CANCER
    • THE LATEST MEDICAL RESEARCH
    • ECAN WEBINARS
    • MORE RESOURCES
  • FOR PATIENTS
    • IF YOU’VE BEEN DIAGNOSED
    • A COMMUNITY FOR SUPPORT
    • CLINICAL TRIALS PORTAL
    • DOWNLOAD THE PATIENT GUIDE
    • Intelligent Nutrition Assistant: Ina®
    • MORE RESOURCES
  • GET INVOLVED
    • JOIN OUR COMMUNITY!
    • JOIN STACY’S ARMY!
    • EVENTS
    • ADVOCATE
  • TRIBUTES
    • IN APPRECIATION WE HONOR
    • MEMORIAL TRIBUTES
    • MAKE AN HONOR OR TRIBUTE GIFT
  • CONTACT
  • DONATE

FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients

The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]

FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer PatientsMindy Mintz Mordecai2021-01-22T01:44:37+00:00

New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma

The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic  HER2+ [...]

New Treatment Option for Patients with HER2+ Gastroesophageal Junction AdenocarcinomaMindy Mintz Mordecai2021-01-21T22:14:22+00:00

Latest US Stats Show More Esophageal Cancer Cases, Fewer Deaths

The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]

Latest US Stats Show More Esophageal Cancer Cases, Fewer DeathsMindy Mintz Mordecai2021-01-21T21:31:57+00:00

Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant Benefits

Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]

Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant BenefitsMindy Mintz Mordecai2020-09-22T00:51:54+00:00

Personalized Approach Shows Survival Benefit in Esophageal Adenocarcinoma

Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]

Personalized Approach Shows Survival Benefit in Esophageal AdenocarcinomaMindy Mintz Mordecai2020-09-22T01:15:19+00:00

Immunotherapy Breakthroughs for Esophageal Cancer Patients

The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]

Immunotherapy Breakthroughs for Esophageal Cancer PatientsMindy Mintz Mordecai2020-09-22T00:53:07+00:00

Barrett’s Esophagus and Esophageal Adenocarcinoma can run in Families

The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]

Barrett’s Esophagus and Esophageal Adenocarcinoma can run in FamiliesMindy Mintz Mordecai2020-08-14T00:07:02+00:00

FDA calls New Screening Test Using DNA to Detect Esophageal Cancer a Breakthrough Device

First Time the FDA has given Breakthrough Designation for a Device Targeting Diseases of the Esophagus. Lucid Diagnostics' EsoGuard™ Esophageal [...]

FDA calls New Screening Test Using DNA to Detect Esophageal Cancer a Breakthrough DeviceMindy Mintz Mordecai2020-08-14T00:39:25+00:00

FDA Approves First Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma

The U.S. Food and Drug Administration has approved Keytruda (Pembrolizumab) for treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC).  It [...]

FDA Approves First Immunotherapy for Advanced Esophageal Squamous Cell CarcinomaMindy Mintz Mordecai2019-08-15T23:40:13+00:00

First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer

First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in [...]

First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Canceradmin2019-01-27T14:12:47+00:00
12Next

 
 

P.O. Box 243, Stevenson, Maryland 21153
410-358-3226 | info@ecan.org

The Internal Revenue Service has designated ECAN Esophageal Cancer Action Network a 501 (c)(3) charity. Donations to ECAN are tax deductible to the full extent of the law.
All content ©2020 by ECAN. All Rights Reserved. Website by New Frame Creative.